Professional Certificate in Cancer Immunotherapy Research & Development
-- ViewingNowThe Professional Certificate in Cancer Immunotherapy Research & Development is a comprehensive course that equips learners with the essential skills needed to excel in this rapidly evolving field. This certificate program provides a deep dive into the latest advances in cancer immunotherapy, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies.
6,033+
Students enrolled
GBP £ 140
GBP £ 202
Save 44% with our special offer
ě´ ęłźě ě ëí´
100% ě¨ëźě¸
ě´ëěë íěľ
ęłľě ę°ëĽí ě¸ěŚě
LinkedIn íëĄíě ěśę°
ěëŁęšě§ 2ę°ě
죟 2-3ěę°
ě¸ě ë ěě
ë기 ę¸°ę° ěě
ęłźě ě¸ëśěŹí
⢠Fundamentals of Cancer Immunotherapy: An introductory unit covering the basic concepts and mechanisms of cancer immunotherapy, including the immune system's role in fighting cancer and various immunotherapeutic approaches.
⢠Immune Checkpoint Inhibitors: This unit delves into the specifics of immune checkpoint inhibitors, a significant class of cancer immunotherapies, discussing their targets, mechanisms of action, and clinical applications.
⢠CAR T-cell Therapy: A unit dedicated to chimeric antigen receptor (CAR) T-cell therapy, which involves genetically modifying a patient's T-cells to recognize and attack cancer cells. This unit should cover CAR T-cell design, manufacturing, and administration.
⢠Monoclonal Antibodies in Cancer Immunotherapy: This unit focuses on monoclonal antibodies, their production, and therapeutic applications in cancer immunotherapy, addressing targets, mechanisms of action, and clinical trials.
⢠Tumor Microenvironment and Immunotherapy: An in-depth examination of the tumor microenvironment, its impact on cancer progression and immunotherapy, including stromal cells, tumor-associated immune cells, and the role of hypoxia and acidosis.
⢠Combination Therapies in Cancer Immunotherapy: This unit covers the rationale, benefits, and challenges of combining immunotherapies with other cancer treatments, such as chemotherapy, radiotherapy, and targeted therapy.
⢠Clinical Trial Design and Translational Research in Cancer Immunotherapy: A unit focusing on the methodologies of clinical trials and translational research in cancer immunotherapy. This unit should address trial design, endpoints, statistical considerations, and biomarker development.
⢠Regulatory Affairs and Commercialization in Cancer Immunotherapy: This unit explores the regulatory landscape, challenges, and opportunities in the
ę˛˝ë Ľ 경ëĄ
ě í ěęą´
- 죟ě ě ëí 기본 ě´í´
- ěě´ ě¸ě´ ëĽěë
- ěť´í¨í° ë° ě¸í°ëˇ ě ꡟ
- 기본 ěť´í¨í° 기ě
- ęłźě ěëŁě ëí íě
ěŹě ęłľě ěę˛Šě´ íěíě§ ěěľëë¤. ě ꡟěąě ěí´ ě¤ęłë ęłźě .
ęłźě ěí
ě´ ęłźě ě ę˛˝ë Ľ ę°ë°ě ěí ě¤ěŠě ě¸ ě§ěęłź 기ě ě ě ęłľíŠëë¤. ꡸ę˛ě:
- ě¸ě ë°ě 기ę´ě ěí´ ě¸ěŚëě§ ěě
- ęśíě´ ěë 기ę´ě ěí´ ęˇě ëě§ ěě
- ęłľě ě겊ě ëł´ěě
ęłźě ě ěąęłľě ěźëĄ ěëŁí늴 ěëŁ ě¸ěŚě뼟 ë°ę˛ ëŠëë¤.
ě ěŹëë¤ě´ ę˛˝ë Ľě ěí´ ě°ëŚŹëĽź ě ííëę°
댏롰 ëĄëŠ ě¤...
ě죟 돝ë ě§ëʏ
ě˝ě¤ ěę°ëŁ
- 죟 3-4ěę°
- 쥰기 ě¸ěŚě ë°°ěĄ
- ę°ë°Ší ëąëĄ - ě¸ě ë ě§ ěě
- 죟 2-3ěę°
- ě 기 ě¸ěŚě ë°°ěĄ
- ę°ë°Ší ëąëĄ - ě¸ě ë ě§ ěě
- ě 체 ě˝ě¤ ě ꡟ
- ëě§í¸ ě¸ěŚě
- ě˝ě¤ ěëŁ
ęłźě ě ëł´ ë°ę¸°
íěŹëĄ ě§ëś
ě´ ęłźě ě ëšěŠě ě§ëśí기 ěí´ íěŹëĽź ěí ě˛ęľŹě뼟 ěě˛íě¸ě.
ě˛ęľŹěëĄ ę˛°ě ę˛˝ë Ľ ě¸ěŚě íë